相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia
Adele Baker et al.
CANCER RESEARCH (2016)
Targeting DNA repair, DNA metabolism and replication stress as anti-cancer strategies
Jordi Carreras Puigvert et al.
FEBS JOURNAL (2016)
Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase
Sebastien L. Degorce et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxylethy]-1,3-dimethyl-piperazin-2-one (AZD5153)
Robert H. Bradbury et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
Garrett W. Rhyasen et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Potent and selective bivalent inhibitors of BET bromodomains
Michael J. Waring et al.
NATURE CHEMICAL BIOLOGY (2016)
SCFCyclin F-dependent degradation of CDC6 suppresses DNA re-replication
David Walter et al.
NATURE COMMUNICATIONS (2016)
Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
Anastasios Stathis et al.
CANCER DISCOVERY (2016)
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
Celine Berthon et al.
LANCET HAEMATOLOGY (2016)
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
Sandy Amorim et al.
LANCET HAEMATOLOGY (2016)
Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer
Kevin M. Foote et al.
FUTURE MEDICINAL CHEMISTRY (2015)
Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non-BRCAness high grade ovarian carcinoma
Oumou Goundiam et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models
Claire Crafter et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Targeting the DNA Damage Response in Cancer
Mark J. O'Connor
MOLECULAR CELL (2015)
Exploiting replicative stress to treat cancer
Matthias Dobbelstein et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Replication Stress in Mammalian Cells and Its Consequences for Mitosis
Camille Gelot et al.
GENES (2015)
An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma
Maria Giuseppina Baratta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
Junwei Shi et al.
MOLECULAR CELL (2014)
Chromatin Reader Brd4 Functions in Ig Class Switching as a Repair Complex Adaptor of Nonhomologous End-Joining
Andre Stanlie et al.
MOLECULAR CELL (2014)
Causes and consequences of replication stress
Michelle K. Zeman et al.
NATURE CELL BIOLOGY (2014)
Chromatin Remodeling at DNA Double-Strand Breaks
Brendan D. Price et al.
CELL (2013)
The bromodomain protein Brd4 insulates chromatin from DNA damage signalling
Scott R. Floyd et al.
NATURE (2013)
Discovery of XL413, a potent and selective CDC7 inhibitor
Elena S. Koltun et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Thr-1989 Phosphorylation Is a Marker of Active Ataxia Telangiectasia-mutated and Rad3-related (ATR) Kinase
Edward A. Nam et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations
Luis I. Toledo et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Carol Kilkenny et al.
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS (2010)
ATRMec1 Phosphorylation-independent Activation of Chk1 in Vivo
Yinhuai Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Synergistic drug combinations tend to improve therapeutically relevant selectivity
Joseph Lehar et al.
NATURE BIOTECHNOLOGY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity
Alessia Montagnoli et al.
NATURE CHEMICAL BIOLOGY (2008)
CDC6:: from DNA replication to cell cycle checkpoints and oncogenesis
Luis R. Borlado et al.
CARCINOGENESIS (2008)
Brd4 recruits P-TER to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression
Zhiyuan Yang et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
DNA repair pathways as targets for cancer therapy
Thomas Helleday et al.
NATURE REVIEWS CANCER (2008)
Cellular response to etoposide treatment
Alessandra Montecucco et al.
CANCER LETTERS (2007)
The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation
Shwu-Yuan Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Chk1- and claspin-dependent but ATR/ATM- and Rad17-independent DNA replication checkpoint response in HeLa cells
Vernica Rodriguez-Bravo et al.
CANCER RESEARCH (2006)
CDK-dependent stabilization of Cdc6 - Linking growth and stress signals to activation of DNA replication
AM Duursma et al.
CELL CYCLE (2005)
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death
R Chen et al.
BLOOD (2005)
CDKs promote DNA replication origin licensing in human cells by protecting Cdc6 from APC/C-dependent proteolysis
N Mailand et al.
CELL (2005)
The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription
MK Jang et al.
MOLECULAR CELL (2005)
ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex
JH Lee et al.
SCIENCE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
The role of Cdc6 in ensuring complete genome licensing and S phase checkpoint activation
M Oehlmann et al.
JOURNAL OF CELL BIOLOGY (2004)
Targeting the checkpoint kinases: Chemosensitization versus chemoprotection
BBS Zhou et al.
NATURE REVIEWS CANCER (2004)
The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis
A Dey et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
A mammalian bromodomain protein, Brd4, interacts with replication factor C and inhibits progression to S phase
T Maruyama et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1
H Zhao et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
分享论文
